What is the Impact Factor of Molecular Therapy-Nucleic Acids?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Molecular Therapy-Nucleic Acids is 6.50, ranking in quartile Q1 of Web of Science (SCIE).

Is Molecular Therapy-Nucleic Acids indexed in Web of Science or Scopus?

Yes, Molecular Therapy-Nucleic Acids is indexed in Web of Science (SCIE, Q1 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 2.068 (Q1) and an H-index of 113.

Who publishes Molecular Therapy-Nucleic Acids and what is the Article Processing Charge (APC)?

Molecular Therapy-Nucleic Acids is published by Cell Press. The estimated Article Processing Charge (APC) is approximately $3,766 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Molecular Therapy-Nucleic Acids?

The official ISO-4 abbreviation of Molecular Therapy-Nucleic Acids is "MOL THER-NUCL ACIDS" with common acronym "mtna". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q1Scopus Q1SCImago #1,346Top JournalGold OA

Molecular Therapy-Nucleic Acids

Acronym:mtna

•

Abbreviation (ISO):MOL THER-NUCL ACIDS

•

Identifier (ISSN):2162-2531(Print)

•

Publisher:Cell Press

Official Website Submission Portal Compare

Clarivate IF (2026)

6.5↑ +0.4

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIETop Tier

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Molecular Therapy-Nucleic Acids

WoS Q1

Annual Impact Factor Metric

Current (2026):6.5

Scopus SJR & RankScopus Q1

2.068

#1,346

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

113

113 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier

Self-Citation RateN/A

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessGold OA

344articles/year

100% Gold OA•92.42% Original Research

Aims & Scope

Molecular Therapy — Nucleic Acids publishes research targeted to the advances in nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Subject areas include: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, and applications of gene-modifying agents.

Topics Covered (Recognized by AI)

Biology99.2%Genetics96.6%Chemistry94.6%Biochemistry93.2%Gene86.3%Medicine82.4%Internal medicine65.5%Cell biology47.9%Cancer research45.8%RNA34.9%microRNA29.6%Cell culture27.8%Cancer26%Apoptosis25.7%Pathology24.6%Molecular biology24%Immunology23.2%Endocrinology20.6%Downregulation and upregulation20.5%Computational biology20.3%

Primary Research Areas

Medicine Research & Experimental

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Rank37/191

IndexSCIE

JCISCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Rank26/191

IndexSCIE

Category	Index	Rank	Quartile
MEDICINE, RESEARCH & EXPERIMENTAL	JCRSCIE	37/191	Q1
MEDICINE, RESEARCH & EXPERIMENTAL	JCISCIE	26/191	Q1

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF6.5

Articles / Year274

Total Citations147

2025

IF6.1

Articles / Year353

Total Citations1,780

2024

IF6.5

Articles / Year308

Total Citations2,914

2023

IF8.8

Articles / Year301

Total Citations5,300

2022

IF10.183

Articles / Year324

Total Citations6,758

Year	Impact Factor	Articles / Year	Total Citations
2026	6.5	274	147
2025	6.1	353	1,780
2024	6.5	308	2,914
2023	8.8	301	5,300
2022	10.183	324	6,758
2021	8.886	336	12,062
2020	7.032	385	19,569
2019	5.919	338	21,892
2018	5.66	218	12,338
2017	—	186	11,103
2016	—	132	6,408
2015	—	55	5,738

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #1,346Scopus Q1SCImago Profile

Scopus Coverage:2012-2026

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyPharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q1

2.068

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

5.38

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,766 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations4,762

3-Year Documents852

Citable Documents712

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate45.2%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Drug DiscoveryQ1

Molecular MedicineQ1

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: N/A

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

2区 (Zone 2)Medicine

Minor Category (Specific Field):

2区MEDICINE, RESEARCH & EXPERIMENTAL

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

In warning list

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Molecular Therapy-Nucleic Acids (acronym: mtna, abbr: MOL THER-NUCL ACIDS, ISSN: 2162-2531) is a peer-reviewed international scholarly journal in the field of MEDICINE, published by Cell Press in United States. The periodical holds a Journal Impact Factor (JIF) of 6.50, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 2.068 (Q1), an H-index of 113.

The journal enforces rigorous peer evaluation with an annual output of approximately 344 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,766 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.